Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07030348 · ClinicalTrials.gov registry record

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

A clinical trial of Pancreatic Diseases and Pancreatic Cancers, sponsored by Do Hyun Park.

Recruiting
Registry status
263
Enrollment target
3
Study locations

NCT07030348 is a study of Pancreatic Diseases and Pancreatic Cancers that is actively recruiting participants, run by Do Hyun Park. The registered enrollment target is 263 participants, below the 1,136-participant average among 5 other Pancreatic Diseases trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07030348, a study of Pancreatic Diseases and Pancreatic Cancers, is actively recruiting participants, sponsored by Do Hyun Park.

RECRUITING
Registry status
263 participants
Enrollment target
3
Study locations

Study Summary

Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.

Study Locations (3)

Colorado

  • University of Colorado Hospital - Aurora

Ohio

  • Cleveland Clinic - Cleveland

Other

  • Asan Medical Center - Seoul

Trial Details

FieldValue
Enrollment Target 263 participants
Start Date 2024-01-02
Est. Completion 2026-12-31

Sponsor

Do Hyun Park

1 total trials

What the Registry Record Tells You About NCT07030348

The ClinicalTrials.gov registry entry for NCT07030348 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,136-participant average among 5 other Pancreatic Diseases trials with a reported enrollment target (77% lower). The listed sponsor is Do Hyun Park, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT07030348 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Ohio, Other.

Frequently Asked Questions

What is clinical trial NCT07030348 about?

NCT07030348 is a clinical study titled "Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study". Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic ca...

What is the current status of trial NCT07030348?

This trial is currently recruiting. The enrollment target is 263 participants. The study started on 2024-01-02. Estimated completion is 2026-12-31.

What conditions does trial NCT07030348 study?

This clinical trial studies the following conditions: Pancreatic Diseases, Pancreatic Cancers.

Who is sponsoring clinical trial NCT07030348?

This trial is sponsored by Do Hyun Park, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07030348 being conducted?

This trial has 3 study locations across Colorado, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.